Daily Cardiology Research Analysis
Analyzed 132 papers and selected 3 impactful papers.
Summary
A phase 2 randomized trial in Nature Medicine showed that the NPR1 agonist antibody XXB750 paradoxically worsened biomarkers and heart failure events, prompting early termination. A multicenter RCT (DKCRUSH VIII) in JACC demonstrated that IVUS guidance during DK-crush bifurcation PCI reduced 1-year target vessel failure versus angiography guidance, while a Circulation: Arrhythmia and Electrophysiology RCT found that extensive electrogram–anatomic ablation improved 3-year outcomes in persistent AF with heart failure.
Research Themes
- Failure signals with novel natriuretic peptide pathway activation in heart failure
- Imaging-guided optimization of complex bifurcation PCI
- Strategy-level advances in AF ablation for patients with concomitant heart failure
Selected Articles
1. The NPR1 agonist antibody XXB750 in heart failure: a phase 2 randomized trial.
In this multicenter phase 2 RCT (n=136), the NPR1 agonist antibody XXB750 increased NT-proBNP (ratio 1.34) and reduced cGMP (ratio 0.77) at 16 weeks, while sacubitril/valsartan showed the opposite biomarker pattern. Death or worsening heart failure events occurred more frequently with XXB750 (25%) versus sacubitril/valsartan (8%) and placebo (0%), leading to early termination.
Impact: A novel NPR1-targeting biologic unexpectedly worsened biomarkers and outcomes in heart failure, providing an important negative signal that redirects drug development within the natriuretic peptide pathway.
Clinical Implications: NPR1 agonist therapy should not be pursued outside trials in heart failure, and caution is warranted given possible functional antagonism. Findings reinforce the clinical value of sacubitril/valsartan and highlight the need for mechanistic studies before advancing receptor-activating biologics.
Key Findings
- XXB750 increased NT-proBNP (ratio 1.34; 95% CI 1.07–1.66) and decreased cGMP (ratio 0.77; 95% CI 0.65–0.91) at 16 weeks.
- Sacubitril/valsartan decreased NT-proBNP (ratio 0.70) and increased cGMP (ratio 1.38).
- Death or worsening HF events were higher with XXB750 (25%) vs sacubitril/valsartan (8%) and placebo (0%), prompting early trial termination.
Methodological Strengths
- Multicenter randomized controlled design with blinded XXB750/placebo arms
- Active comparator (sacubitril/valsartan) anchoring mechanistic signal and clinical relevance
Limitations
- Phase 2 sample size with surrogate primary endpoint (NT-proBNP)
- Open-label sacubitril/valsartan arm and early termination may limit precision and generalizability
Future Directions: Mechanistic studies to elucidate NPR1 signaling and potential functional antagonism; exploration of dose–receptor dynamics and tissue-specific effects; careful safety-led design for future natriuretic peptide pathway therapeutics.
Therapies targeting the natriuretic peptide system have the potential to reduce death or heart failure events in heart failure with reduced ejection fraction. Here we assess XXB750, a human monoclonal antibody activating natriuretic peptide receptor 1, in patients with heart failure. Patients with heart failure and a left ventricular ejection fraction <50% were enrolled. Those patients who were on background angiotensin-converting enzyme inhibitor or angiotensin receptor blocker treatment were randomized to receive 60 mg XXB750, 120 mg XXB750 or placebo in a blinded fashion or sacubitril/valsartan treatment in an open-label fashion. Those patients on background sacubitril/valsartan treatment were randomized to either 60 mg XXB750, 120 mg XXB750 or placebo treatment in a blinded fashion. The primary endpoint was the change in NT-proBNP levels at 16 weeks after treatment initiation, and safety was also assessed. We randomized 136 participants (70% male, 30% female) to 60 mg XXB750 (n = 26), 120 mg XXB750 (n = 55), matching placebo (n = 29) or sacubitril/valsartan (n = 25). At 16 weeks, NT-proBNP levels rose (ratio of change from baseline 1.34, 95% confidence interval (CI) 1.07-1.66) and cyclic guanosine monophosphate (cGMP) levels declined (ratio of change from baseline 0.77, 95% CI 0.65-0.91) in the pooled XXB750 arms, whereas NT-proBNP levels declined from baseline (ratio of change from baseline 0.70, 95% CI 0.45-1.10), and cGMP levels rose (ratio of change from baseline 1.38, 95% CI 1.13-1.69) in the sacubitril/valsartan arm.
2. IVUS or Angiography Guidance for Percutaneous Coronary Intervention in Complex Coronary Bifurcation Lesions: The DKCRUSH VIII Randomized Clinical Trial.
In 555 patients with complex bifurcation lesions (DK-crush in 96.8%), IVUS-guided PCI reduced 1-year target vessel failure from 14.7% to 6.1% (HR 0.40), driven by fewer target vessel MI and revascularizations. Nearly half involved left main bifurcations, supporting IVUS optimization targets in complex anatomy.
Impact: Provides high-quality randomized evidence that IVUS-guided optimization improves hard outcomes in complex bifurcation PCI using DK-crush.
Clinical Implications: For complex bifurcation PCI, particularly with DK-crush and left main involvement, routine IVUS-guided optimization should be considered to reduce MI and repeat revascularization.
Key Findings
- Primary endpoint (target vessel failure at 1 year) reduced with IVUS guidance: 6.1% vs 14.7% (HR 0.40; 95% CI 0.23–0.71; P=0.002).
- Benefit driven by fewer target vessel MI and clinically driven target vessel revascularizations.
- Left main bifurcation involvement in ~45% of cases; DK-crush used in 96.8%.
Methodological Strengths
- Multicenter randomized trial with prespecified DEFINITION criteria for lesion complexity
- Clinically meaningful composite primary endpoint at 1 year
Limitations
- Open-label design and single-country enrollment (China) may limit generalizability
- Follow-up limited to 1 year; cost-effectiveness and longer-term outcomes not assessed
Future Directions: Assess long-term outcomes, operator learning curves, and cost-effectiveness; evaluate applicability across geographies and alternative bifurcation strategies.
BACKGROUND: Intravascular ultrasound (IVUS)-guided percutaneous coronary intervention (PCI) is associated with fewer clinical events than angiography-guided PCI. Whether the use of IVUS guidance improves the outcomes as compared with angiography guidance in patients with complex coronary bifurcation lesion undergoing double kissing (DK) crush is uncertain. OBJECTIVES: This study aimed to investigate the treatment effect of IVUS-guided PCI, as compared with angiography-guided PCI, in patients with complex bifurcation lesions. METHODS: We conducted a multicenter, randomized, open-label trial at 24 centers in China. Patients with clinical indications for PCI and a complex bifurcation lesion based on DEFINITION (Definitions and Impact of Complex Bifurcation Lesions on Clinical Outcomes After Percutaneous Coronary Intervention Using Drug-Eluting Stents) criteria (particularly side branch lesion length ≥10 mm) from coronary angiography were randomly assigned in a 1:1 ratio to IVUS-guided PCI or angiography-guided PCI. The primary endpoint was a composite of target vessel failure, defined as cardiac death, target vessel myocardial infarction, or clinically driven target vessel revascularization at 1 year after randomization. RESULTS: We assigned 555 patients to IVUS-guided PCI (n = 277) or angiography-guided PCI (n = 278). A total of 124 patients (44.8%) in the IVUS-guided PCI group and 122 (43.9%) in the angiography-guided PCI group had a bifurcation lesion involving the left main coronary artery. DK crush was used in 96.8% of patients. At 1 year, a primary endpoint event occurred in 17 patients (6.1%) in the IVUS-guided PCI group and in 41 patients (14.7%) in the angiography-guided PCI group (HR: 0.40; 95% CI: 0.23-0.71; P = 0.002), driven mainly by reductions in target vessel myocardial infarction or target vessel revascularization. CONCLUSIONS: In the present randomized trial comparing IVUS-guided vs angiography-guided PCI for complex coronary bifurcation lesions treated with the 2-stent DK crush technique, the benefits of IVUS-guided PCI at 1 year was achieved largely through achievement of IVUS-defined optimization targets rather than IVUS use alone.
3. Optimal Ablation Strategies for Persistent Atrial Fibrillation With Heart Failure: Three-Year Follow-Up of a Prospective Multicenter Randomized Trial.
In 300 patients with persistent AF and HF (both HFrEF and HFpEF), extensive electrogram–anatomic ablation yielded the lowest 36-month composite of CV death or HF hospitalization/urgent visit (17% vs 29% vs 36%) and the highest sinus rhythm maintenance. Secondary endpoints including AF burden, NYHA class, 6MWT, and NT-proBNP favored the extensive strategy.
Impact: Defines a strategy-level approach that improves long-term outcomes and rhythm control in a high-risk population with persistent AF and HF, informing procedural planning beyond PVI alone.
Clinical Implications: For persistent AF with HF, combining electrogram-guided lesion targeting with anatomic ablation provides superior outcomes across EF phenotypes and may be considered when selecting ablation strategies.
Key Findings
- Extensive electrogram–anatomic ablation reduced 36-month composite events (17%) vs electrogram-guided (29%) and anatomic-guided (36%).
- Sinus rhythm maintenance at 36 months was highest with the extensive strategy.
- Benefits were consistent across HFrEF and HFpEF subgroups; secondary endpoints (AF burden, NYHA class, 6MWT, NT-proBNP) improved.
Methodological Strengths
- Prospective multicenter randomized controlled design with 3 parallel strategies
- Long-term (36-month) co-primary clinical and rhythm endpoints with prespecified HF subgroup analyses
Limitations
- Incomplete reporting of absolute rhythm metrics and procedural details in abstract; blinding not feasible
- Technique heterogeneity and operator dependence may affect reproducibility across centers
Future Directions: Standardize lesion sets and mapping criteria; assess safety, durability, and cost-effectiveness; refine patient selection and integration with guideline-directed HF therapy.
BACKGROUND: Catheter ablation has been shown to improve prognosis in patients with heart failure (HF) and atrial fibrillation (AF); however, the optimal ablation strategy remains undefined. METHODS: In this multicenter, randomized controlled trial, 300 patients with persistent AF and HF, including both HF with reduced ejection fraction (EF ≤40%) and HF with preserved ejection fraction (EF >40%, including mid-range EF [EF 41% to 50%]), were enrolled and randomized equally to the anatomic-guided ablation, electrogram-guided ablation, and extensive electrogram-anatomic-guided ablation groups, with 100 patients in each group. The coprimary end points were: (1) the composite of cardiovascular death or HF-related hospitalization/urgent visit within 36 months; and (2) maintenance of sinus rhythm at 36 months. Secondary end points included AF burden <1%, New York Heart Association class improvement (≥1 grade), 6-minute walk test change, NT-proBNP (N-terminal pro-B-type natriuretic peptide) reduction, and procedure-related complications. Subgroup analyses were performed for HF with reduced ejection fraction and HF with preserved ejection fraction. RESULTS: At 36 months, the extensive electro-anatomic-guided ablation group demonstrated the lowest incidence of the composite end point (17.0%) compared with the electrogram-guided ablation (29.0%) and anatomic-guided ablation (36.0%; overall CONCLUSIONS: Electrogram-anatomic ablation provides superior long-term rhythm control, reduces cardiovascular events, and improves symptoms in patients with persistent AF and HF, regardless of ejection fraction. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT07153718.